Login / Signup

Structure-guided discovery of a single-domain antibody agonist against human apelin receptor.

Yanbin MaYao DingXianqiang SongXiaochuan MaXun LiNing ZhangYunpeng SongYaping SunYuqing ShenWenge ZhongLiaoyuan A HuYingli MaMei-Yun Zhang
Published in: Science advances (2020)
Developing antibody agonists targeting the human apelin receptor (APJ) is a promising therapeutic approach for the treatment of chronic heart failure. Here, we report the structure-guided discovery of a single-domain antibody (sdAb) agonist JN241-9, based on the cocrystal structure of APJ with an sdAb antagonist JN241, the first cocrystal structure of a class A G protein-coupled receptor (GPCR) with a functional antibody. As revealed by the structure, JN241 binds to the extracellular side of APJ, makes critical contacts with the second extracellular loop, and inserts the CDR3 into the ligand-binding pocket. We converted JN241 into a full agonist JN241-9 by inserting a tyrosine into the CDR3. Modeling and molecular dynamics simulation shed light on JN241-9-stimulated receptor activation, providing structural insights for finding agonistic antibodies against class A GPCRs.
Keyphrases
  • endothelial cells
  • molecular dynamics simulations
  • small molecule
  • high throughput
  • molecular docking
  • pluripotent stem cells
  • single cell
  • replacement therapy